Cocrystal Pharma, Inc. - COCP STOCK NEWS

Cocrystal Pharma (Nasdaq: COCP) has entered into a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to conduct exploratory preclinical studies on its SARS-CoV-2 3CL protease inhibitors for potential COVID-19 treatment. Cocrystal's novel inhibitors demonstrate potent in vitro efficacy against SARS-CoV-2 and variants, including Omicron. This collaboration aims to further evaluate the antiviral activity of these compounds in both in vitro and in vivo settings.

Cocrystal Pharma (Nasdaq: COCP) will present at the Life Science Innovation Northwest 2022 conference on April 20-21, 2022, at the Washington State Convention Center in Seattle. Sam Lee, PhD, President and co-interim CEO, is set to deliver a presentation during the Neuroscience & Pharmaceuticals segment on April 20 at 3:25 PM Pacific. This conference is the Pacific Northwest’s largest annual life science event, aiming to connect investors, researchers, and organizations to discuss significant life science breakthroughs.

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that James Martin, Chief Financial Officer and co-interim CEO, will present at the NobleCon18 Investor Conference on April 21, 2022, at 9:30 a.m. ET, held at the Hard Rock Hotel & Casino in Hollywood, Florida. A video webcast of the presentation will be available the next day on the Company's website, as well as on Noble Capital Markets’ and Channelchek's websites, archived for 90 days.

Cocrystal, a clinical-stage biotechnology company, focuses on developing novel antiviral therapeutics targeting various viruses.

Cocrystal Pharma, Inc. (COCP) announced preliminary results from its Phase 1 study of CC-42344, an oral antiviral targeting influenza A. The study, involving 56 healthy participants, demonstrated a favorable safety and pharmacokinetic profile with promising oral bioavailability and dose-dependent plasma exposures. CC-42344 is designed to address pandemic and seasonal influenza strains, aiming to be a best-in-class treatment option. Full results are expected later in 2022, affirming Cocrystal's commitment to advancing antiviral therapies.

Cocrystal Pharma, Inc. (Nasdaq: COCP) has commenced enrollment in a Phase 1 trial for CC-42344, an orally administered antiviral for influenza A. The company plans to initiate two additional Phase 1 trials in 2022 for COVID-19 antiviral candidates. Notably, Cocrystal reported no revenues for 2021, down from $2 million in 2020, and a net loss of $14.2 million, or $0.16 per share. However, cash reserves increased to $58.7 million, up from $33 million year-over-year, providing sufficient funds for operations through 2023.

Cocrystal Pharma, Inc. (Nasdaq: COCP) will participate in the 2022 Virtual Growth Conference hosted by Maxim Group and M-Vest from March 28-30, 2022. Interested attendees can register online. A pre-recorded presentation will be accessible for 72 hours starting March 28 at 9:00 a.m. ET. Cocrystal Pharma is focused on developing antiviral therapeutics targeting influenza, coronaviruses, hepatitis C, and noroviruses, utilizing advanced technologies and expertise.

Cocrystal Pharma has initiated dosing in a Phase 1 clinical trial for its antiviral drug CC-42344, targeting both pandemic and seasonal influenza A. Conducted in Australia, this study will assess the drug's safety and pharmacokinetics in 56 healthy adults. CC-42344 is designed to inhibit influenza viral replication and potentially act against drug-resistant strains. Results are expected later this year, marking a key step in Cocrystal's development of innovative antiviral therapies.

Cocrystal Pharma (Nasdaq: COCP) announces participation in two investment conferences. The Q1 Investor Summit on March 8-9 will feature a presentation on March 9 at 11:45 a.m. Eastern time. Additionally, the company will attend the 34th Annual Roth Conference from March 13-15 in California. Cocrystal plans to start enrollment for a Phase 1 trial of influenza A and initiate studies on two SARS-CoV-2 antivirals for COVID-19 treatments. The company emphasizes its strong financial position to support these developments.

Cocrystal Pharma (Nasdaq: COCP) announced the selection of two investigational oral antiviral candidates, CDI-988 and CDI-873, for the treatment of SARS-CoV-2, showing superior in vitro potency against the virus and its variants, including Omicron.

Both candidates are poised for first-in-human trials in 2022, leveraging Cocrystal's proprietary drug discovery platform. The company also plans to expedite the development of an inhalation candidate, CDI-45205. Positive preclinical results and FDA guidance for CDI-45205 support upcoming clinical study plans.